Oric Pharmaceuticals Adopts Amended Inducement Equity Plan, Adds 1.1M Shares

What Happened

• Oric Pharmaceuticals (ORIC) filed an 8-K reporting that on July 28, 2026 its Board approved an Amended and Restated 2022 Inducement Equity Incentive Plan to increase the pool of shares available for inducement awards. The Board reserved an additional 1,100,000 shares of common stock, bringing the total reserved under the Inducement Plan to 3,350,000 shares. The plan was adopted without stockholder approval under applicable Nasdaq listing rules.

Key Details

• Board approval date: July 28, 2026.
• Additional shares reserved: 1,100,000; total reserved under the Inducement Plan: 3,350,000.
• Types of awards allowed: nonstatutory stock options, restricted stock units (RSUs), restricted stock, stock appreciation rights, performance shares and performance stock units.
• Awards under the Inducement Plan are limited by Nasdaq rules to individuals who are new hires (or after a bona fide period of non‑employment) or, as permitted, in connection with a merger/acquisition. The plan’s terms are substantially similar to ORIC’s 2020 Equity Incentive Plan and provide for treatment of awards in a “merger” or “change in control.”

Why It Matters

• This increases the company’s ability to grant equity awards to attract and retain new employees and executives without seeking immediate shareholder approval, which can speed hiring and integration in competitive talent situations.
• The additional share reserve could dilute existing shareholders over time if awards are exercised or vested; investors should monitor future grants, the company’s share usage, and any related compensation expense in ORIC’s filings.
• The plan’s use of Nasdaq inducement and acquisition exceptions means grants will mainly target new hires or M&A-related transactions rather than current employees or directors.